Showing 1 posts of 1 posts found.
Elacestrant is the first tailored treatment for certain people with oestrogen receptor (ER)-positive HER2-negative locally advanced and metastatic breast cancer …
Care Quality Commission appoints Emily Miles as Chief Executive
National survey aims to improve glaucoma care across the UK
Phase 3 trials support expanded use of Dysport for migraine prevention
Roche secures CE Mark for automated latent tuberculosis blood test
ReproNovo Phase 2 fertility study doses first participant